Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/5974
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kerr, D. | - |
dc.contributor.author | Ong, J. | - |
dc.date.issued | 1996 | - |
dc.identifier.citation | Drug Discovery Today, 1996; 1(9):371-380 | - |
dc.identifier.issn | 1359-6446 | - |
dc.identifier.uri | http://hdl.handle.net/2440/5974 | - |
dc.description.abstract | GABA is a major inhibitory neurotransmitter in the CNS where it regulates neuronal excitability. These actions of GABA are mediated through GABA receptor sub-types, one of which is the GABAB receptor (GBR). The development of specific agonists and antagonists for GBRs has led to a better understanding of their functional roles, which mainly focus on the long-term modulation of neural activity. In this review, the authors emphasize the current knowledge of the structure-action profile of compounds active at GBRs, characterizing their physiology and pharmacology and highlighting their potential as targets for drug development. | - |
dc.language.iso | en | - |
dc.publisher | Elsevier BV | - |
dc.source.uri | http://dx.doi.org/10.1016/1359-6446(96)10034-9 | - |
dc.title | GABAB receptors: targets for drug development | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1016/1359-6446(96)10034-9 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Ong, J. [0000-0002-0958-460X] | - |
Appears in Collections: | Anaesthesia and Intensive Care publications Aurora harvest 5 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.